Role of Fibrocytes in Chronic Obstructive Pulmonary Disease

Overview

Chronic obstructive pulmonary disease (COPD) is a frequent airway disease characterized by both bronchial inflammation and remodelling.

Bronchial mucosa is infiltrated by macrophages, neutrophils and lymphocytes. In addition, the number of eosinophils can be also increased during exacerbation.

Airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. It also influences the prognosis of COPD and its mechanisms remain largely unknown. The role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. However, the recruitment of blood fibrocytes and their involvement in COPD airway remodelling remain unknown.

Full Title of Study: “Role of Fibrocytes in the Bronchial Remodeling of Chronic Obstructive Pulmonary Disease”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: September 2016

Interventions

  • Procedure: blood sample
    • blood sample for fibrocytes analysis
  • Procedure: Clinical and functional evaluation
    • Plethysmography, Carbon monoxide capacity of transfer , arterial gaz

Arms, Groups and Cohorts

  • Chronic obstructive pulmonary disease patients
    • COPD patients with exacerbation will be recruited during hospitalization in Intensive care unit or as outpatients in the clinical investigation centre of the CHU de Bordeaux. Inclusion visit: blood sample for fibrocytes analysis. Second visit 2 months ± 7 days after the exacerbation: clinical and functional evaluation (plethysmography, TLCO, arterial gaz), blood sample for fibrocytes analysis.
  • Control group
    • Subjects without any history of lung disease and with normal lung function testing

Clinical Trial Outcome Measures

Primary Measures

  • Number of circulating blood fibrocytes
    • Time Frame: Day 1
    • Sampling of blood in Chronic obstructive pulmonary disease patients
  • Number of circulating blood fibrocytes
    • Time Frame: 2 months
    • Sampling of blood in Chronic obstructive pulmonary disease patients

Secondary Measures

  • Characterization of fibrocytes
    • Time Frame: Day 1 and at 2 months
    • Sampling of blood
  • Differenciation of blood fibrocytes
    • Time Frame: Day 1 and at 2 months
    • Sampling of blood
  • Chemotactism of blood fibrocytes
    • Time Frame: Day 1 and at 2 months
    • Sampling of blood
  • Number of exacerbation
    • Time Frame: 12 months after V2
  • Mortality
    • Time Frame: 12 months after V2
  • Annual decline of ventilatory function
    • Time Frame: 12 months after V2

Participating in This Clinical Trial

Inclusion Criteria

  • Patients: diagnostic of Chronic obstructive pulmonary disease (COPD) exacerbation.
  • Control group: subjects without any history of lung disease and with normal lung function testing. Subjects will be separated in 2 sub-groups according to smoking history (Never smokers, smokers (former or current) and paired to patients according to age and sex.
  • Written informed consent

Exclusion Criteria

  • Subject without any social security or health insurance
  • Asthma, lung fibrosis or idiopathic pulmonary hypertension
  • Chronic viral infections (hepatitis, HIV)

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University Hospital, Bordeaux
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Patrick BERGER, PUPH, Principal Investigator, University Hospital Bordeaux (France)
  • Overall Contact(s)
    • Patrick BERGER, PUPH, (0)5 57 65 65 13

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.